Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antares Pharma, focused on self-injection delivery technologies and topical gel-based pharmaceutical products, has reported total revenue of $3.54m, an increase of 16%, for the second quarter ended 30 June 2011, compared to $3.05m for the same period in 2010.
Subscribe to our email newsletter
Antares’ net loss was $1.554m, or $0.02 loss per diluted share, compared to net loss of $1.552m, or $0.02 loss per diluted share, for the same period in 2010.
The company’s operating loss for the second quarter of 2011 was $1.6m, compared to operating loss of $1.55m for the same period in 2010.
For the six months ended 30 June 2011, the company reported total revenue of $7.11m, compared to $6.42m for the same period in 2010.
The company has reported net loss of $2.94m or 0.03 loss per diluted share for the six months ended 30 June 2011, as compared to $3.16m or $0.04 loss per diluted share for the same period in 2010.
Antares’ operating loss was $3.01m for the six months of 2011, compared to $3.14m for the same period in 2010.
Antares president and CEO Paul Wotton said their year to date product sales increased 46% over the prior year and equally important their year to date royalty revenue mostly attributable to hGH product increased 63% year over year.
"In the R&D area we are completing the development work for Anturol in anticipation of potential FDA approval of this unique product as well as advancing our next potential product, Vibex MTX, through clinical development for the treatment of Rheumatoid Arthritis," Wotton said.